Drug recall · July 19, 2023
Amlodipine Besylate Tablets recall
Why: Subpotent Drug: Out-of-Specification test results observed in assay test at 21-month long term stability study.
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
Amlodipine Besylate Tablets, USP 10 mg, 1000-count bottles, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202 U.S, Manufactured by: Lupin Limited, Aurangabad 431 210 India, NDC 68180-721-03
- Lots / codes
Lot #: A102887, Exp. 6/2023
- Quantity
- 3,096 bottles
- Company
- Lupin Pharmaceuticals Inc., Baltimore, MD
- Distribution
- Product was distributed directly to three distributors in TN and NJ. Product may have been further distributed throughout the United States.
- Initiated
- June 27, 2023 · Voluntary: Firm initiated
- Classified
- July 7, 2023
- Reported
- July 19, 2023
- Ended
- March 12, 2024
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Amlodipine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.